Systemic peptide delivery via the stomach: In vivo evaluation of an oral dosage form for salmon calcitonin

Journal of Controlled Release

Volumn 92, Issue 1-2, 2003, Pages 125-135

  Guggi, Davide ^a   Krauland, Alexander H ^a   Bernkop Schnürch, Andreas ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Pepsin inhibitor; Reduced glutathione; Salmon calcitonin; Stomach targeted oral delivery system; Thiolated chitosan

Indexed keywords

CALCIUM; DEGRADATION; ENZYME IMMOBILIZATION; POLYPEPTIDES;

PEPTIDE DELIVERY;

DRUG PRODUCTS;

CALCIUM; CHITOSAN 4 THIOBUTYLAMIDINE; CHITOSAN DERIVATIVE; CHITOSAN PEPSTATIN A; CYANAMIDE; GLUTATHIONE; PEPSTATIN DERIVATIVE; SALCATONIN; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM BLOOD LEVEL; CHEMICAL MODIFICATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; COVALENT BOND; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG SYNTHESIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; STOMACH JUICE; TABLET FORMULATION;

EID: 0141518595     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(03)00299-2     Document Type: Article

References (25)

1. Meyer B.R., Kreis W., Eschbach J. Transdermal versus subcutaneous leuprolide: a comparison of acute pharmacodynamic effect. Clin. Phamacol. Ther. 48:1990;340-345.
2. Shah R.B., Ahsan F., Khan M.A. Oral delivery of proteins: progress and prognostication. Crit. Rev. Ther. Drug Carrier Syst. 19:2002;135-169.
3. Woodley J.F. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst. 11:1994;61-95.
4. Bernkop-Schnürch A., Schwarz V., Steininger S. Polymers with thiol groups: a new generation of mucoadhesive polymers? Pharm. Res. 16:1999;876-881.
5. Bernkop-Schnürch A., Hornof M., Zoidl T. Thiolated polymers - thiomers: modification of chitosan with 2-iminothiolane. Int. J. Pharm. 260:2003;229-237.
6. Clausen A.E., Bernkop-Schnürch A. In vitro evaluation of the permeation-enhancing effect of thiolated polycarbophil. J. Pharm. Sci. 89:2000;1253-1261.
7. Clausen A.E., Kast C.E., Bernkop-Schnürch A. The role of glutathione in the permeation enhancing effect of thiolated polymers. Pharm. Res. 19:2002;602-608.
8. Kast C.E., Guggi D., Langoth N., Bernkop-Schnürch A. Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. Pharm. Res. 20:2003;931-936.
9. A. Bernkop-Schnürch, C.E. Kast, D. Guggi, Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems, J. Control. Rel. (2003) in press.
10. Sakuma S., Ishida Y., Sudo R., Suzuki N., Kikuchi H., Hitawari K., Kishida A., Akashi M., Hayashi M. Stabilization of salmon calcitonin by polystyrene nanoparticles having surface hydrophilic polymeric chains, against enzymatic degradation. Int. J. Pharm. 159:1997;181-189.
11. Cho Y.-K., Rebholz K.L., Northrop D.B. Solvent isotope effects on the onset of inhibition of porcine pepsin by pepstatin. Biochemisrtry. 33:1994;9637-9642.
12. Marschütz M.K., Bernkop-Schnürch A. Oral peptide drug delivery: polymer-inhibitor conjugates protecting insulin from enzymatic degradation in vitro. Biomaterials. 21:2000;1499-1507.
13. McConnell R.M., Frizell D., Evans A.C.A., Jones W., Cagle C. New pepstatin analogues: synthesis and pepsin inhibition. J. Med. Chem. 34:1991;2298-2300.
14. Coupe A.J., Davis S.S., Wilding I.R. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm. Res. 8:1991;360-364.
15. Baluom M., Friedman D.I., Rubinstein A. Absorption enhancement of calcitonin in the rat intestine by carbopol-containing submicron emulsions. Int. J. Pharm. 154:1997;235-243.
16. Bernkop-Schnürch A. Chitosan and its derivatives: potential excipients for peroral peptide delivery systems. Int. J. Pharm. 194:2000;1-13.
17. Lee Y.-H., Sinko P.J. Oral delivery of salmon calcitonin. Adv. Drug Deliv. Rev. 42:2000;225-238.
18. Takeuchi H., Yamamoto H., Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Deliv. Rev. 47:2001;39-54.
19. Marschütz M.K., Caliceti P., Bernkop-Schnürch A. Design and in vivo evaluation of an oral delivery system for insulin. Pharm. Res. 17:2000;1468-1474.
20. Ch'ng H.S., Park H., Kelly P., Robinson J.R. Bioadhesive polymers as platforms for oral controlled drug delivery. II: Synthesis and evaluation of some swelling, water-insoluble bioadhesive polymers. J. Pharm. Sci. 74:1985;399-405.
21. Langguth P., Merkle H.P., Amidon G. Oral absorption of peptides - the effect of absorption side and enzyme inhibition on the systemic availability of metkephamid. Pharm. Res. 11:1994;528-535.
22. Yamamoto A., Taniguchi T., Rikyun K., Tsuji T., Fujita T., Murakami M., Muranishi S. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res. 11:1994;1496-1500.
23. Bernkop-Schnürch A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Control. Rel. 52:1998;1-16.
24. McCaffrey G., Jamieson J.C. Evidence for the role of a cathepsin D-like activity in the release of gal β-1,4-glnac α-2,6-sialyltransferase from rat and mouse liver in whole-cell systems. Comp. Biochem. Phys. C. 104:1993;91-94.
25. Plumpton C., Kalinka S., Martin R.C., Horton J.K., Davenport A.P. Effects of phosphoramidon and pepstatin A on the secretion of endothelin-1 and big endothelin-1 by human μmbilical vein endothelial cells - measurement by two-site enzyme-linked immunosorbent assay. Clin. Sci. 87:1994;245-251.